Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Sarcoma 1Myeloid 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 17Peritoneal Neoplasms 13Fallopian Tube Neoplasms 10Colorectal Neoplasms 8Stomach Neoplasms 5Carcinoma, Ovarian Epithelial 5Hyperthermia 3Gastrointestinal Neoplasms 3Appendiceal Neoplasms 3Adrenocortical Carcinoma 3Sarcoma 2Rhabdomyosarcoma 2Neoplasms 2Mesothelioma, Malignant 2Mesothelioma 2Glioma 2Glioblastoma 2Desmoplastic Small Round Cell Tumor 2Colonic Neoplasms 2Carcinoma 2Brain Neoplasms 2Adenoma, Islet Cell 2Wilms Tumor 1Retroperitoneal Neoplasms 1Recurrence 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pleural Effusion, Malignant 1Peritoneal Cavity Cancer 1Pelvic Neoplasms 1

Interventions

Cisplatin 57Pemetrexed 45pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10atezolizumab 8Drug Therapy 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Mesothelioma, Malignant × Cytoreduction Surgical Procedures × Clear all
NCT04213794 2025-02-20

TOASTIT

Mayo Clinic

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡